Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.
Several other research analysts also recently commented on SRPT. Zacks Investment Research downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 15th. UBS restated an “outperform” rating and set a $56.51 price objective (down from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Oppenheimer restated a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. HC Wainwright set a $75.00 price objective on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $78.87.
SRPT opened at $80.80 on Friday. The firm has a market cap of $5,380.86, a price-to-earnings ratio of -49.27 and a beta of 1.29. Sarepta Therapeutics has a 52 week low of $28.82 and a 52 week high of $84.37. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The firm had revenue of $57.30 million for the quarter, compared to analysts’ expectations of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The company’s revenue for the quarter was up 961.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.71) earnings per share. equities research analysts forecast that Sarepta Therapeutics will post -1.18 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Hall Laurie J Trustee boosted its position in shares of Sarepta Therapeutics by 2,430.8% in the 4th quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 3,160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Sarepta Therapeutics by 39.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 977 shares in the last quarter. Prentiss Smith & Co. Inc. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $199,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $217,000. Finally, Aperio Group LLC acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $219,000. 84.98% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “BidaskClub Upgrades Sarepta Therapeutics (SRPT) to Strong-Buy” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/15/bidaskclub-upgrades-sarepta-therapeutics-srpt-to-strong-buy.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.